SPRINTEC Drug Patent Profile
✉ Email this page to a colleague
When do Sprintec patents expire, and what generic alternatives are available?
Sprintec is a drug marketed by Barr and is included in one NDA.
The generic ingredient in SPRINTEC is ethinyl estradiol; norgestimate. There are twenty-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norgestimate profile page.
Summary for SPRINTEC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 2 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for SPRINTEC |
Drug Sales Revenues: | Drug sales revenues for SPRINTEC |
DailyMed Link: | SPRINTEC at DailyMed |
Recent Clinical Trials for SPRINTEC
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Society of Family Planning | Phase 1 |
University of Pennsylvania | Phase 1 |
American Heart Association | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for SPRINTEC
US Patents and Regulatory Information for SPRINTEC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Barr | SPRINTEC | ethinyl estradiol; norgestimate | TABLET;ORAL-28 | 075804-001 | Sep 25, 2002 | AB | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |